Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformati… Read more
Verastem Inc (VSTM) - Total Assets
Latest total assets as of September 2025: $176.85 Million USD
Based on the latest financial reports, Verastem Inc (VSTM) holds total assets worth $176.85 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Verastem Inc - Total Assets Trend (2010–2024)
This chart illustrates how Verastem Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Verastem Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Verastem Inc's total assets of $176.85 Million consist of 93.5% current assets and 6.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 87.5% |
| Accounts Receivable | $200.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Verastem Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verastem Inc's current assets represent 93.5% of total assets in 2024, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 87.5% of total assets in 2024, down from 99.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Verastem Inc Competitors by Total Assets
Key competitors of Verastem Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Verastem Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Verastem Inc generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Verastem Inc is currently not profitable relative to its asset base.
Verastem Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.58 | 3.23 | 8.48 |
| Quick Ratio | 2.55 | 3.23 | 8.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $94.34 Million | $ 83.29 Million | $ 127.84 Million |
Verastem Inc - Advanced Valuation Insights
This section examines the relationship between Verastem Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.35 |
| Latest Market Cap to Assets Ratio | 2.86 |
| Asset Growth Rate (YoY) | -32.2% |
| Total Assets | $101.54 Million |
| Market Capitalization | $290.52 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Verastem Inc's assets at a significant premium ( 2.86x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Verastem Inc's assets decreased by 32.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Verastem Inc (2010–2024)
The table below shows the annual total assets of Verastem Inc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $101.54 Million | -32.18% |
| 2023-12-31 | $149.72 Million | +57.51% |
| 2022-12-31 | $95.05 Million | -12.53% |
| 2021-12-31 | $108.66 Million | -29.60% |
| 2020-12-31 | $154.35 Million | +6.41% |
| 2019-12-31 | $145.05 Million | -47.68% |
| 2018-12-31 | $277.24 Million | +208.76% |
| 2017-12-31 | $89.79 Million | +7.37% |
| 2016-12-31 | $83.63 Million | -26.05% |
| 2015-12-31 | $113.09 Million | +14.64% |
| 2014-12-31 | $98.65 Million | -21.25% |
| 2013-12-31 | $125.26 Million | +34.80% |
| 2012-12-31 | $92.92 Million | +57.40% |
| 2011-12-31 | $59.04 Million | +1538.10% |
| 2010-12-31 | $3.60 Million | -- |